← Back to searchRecruitingRecruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT06780670 · Novartis
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
PSMAcTION: A Phase II/III, Open-label, International, Multicenter, Randomized Study of AAA817 Versus Standard of Care in the Treatment of Adult Participants With PSMA Positive Metastatic Castration-resistant Prostate Cancer Who Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
About this study
Study CAAA817A12201 consists of 2 parts: a randomized, open-label, international, multicenter, phase II study (Phase II) to collect more information to support the proposed dose of AAA817 and a randomized, open-label, international, multicenter, 2- arm phase III study (Phase III) aimed to evaluate the efficacy and safety of proposed dose of AAA817 vs. investigator's choice of standard of care (SoC) in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who had treatments with ARPI and taxane-based chemotherapy, and progressed on or after \[177Lu\]Lu-PSMA targeted therapy. The purpose of the phase II part (Phase II) of this study is to collect additional information to support proposed phase III dose of AAA817.
Eligibility criteria
Inclusion Criteria: ∙
* adults ≥ 18 years of age.
* ECOG performance status of 0 to 2.
* histopathological and/or cytological confirmation of adenocarcinoma of the prostate.
* PSMA-positive disease as assessed by PSMA PET/CT scan using an approved PSMA imaging agent as protocol instructed,
* castrate level of serum/plasma testosterone (\< 50 ng/dL or \< 1.7 nmol/L).
* Prior treatments with an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy, and progressed on or after \[177Lu\]Lu-PSMA targeted therapy.
* ≥ 1 metastatic lesion that is present on screening/baseline CT, MRI, or bone scan imaging obtained ≤ 28 days prior to randomization
* eGFR as requested by the sponsor
Exclusion Criteria:
* Any investigational agents within 28 days prior to the day of randomization.
* Any 225Ac-based investigational compound used prior to the day of randomization.
* Participants with a history of CNS metastases who are neurologically unstable, symptomatic, or receiving corticosteroids for the purpose of maintaining neurologic integrity.
* Concurrent acute kidney injury (renal failure developed between 48 hours to 7 days) or chronic kidney disease (at least 3 months of ongoing renal injury)
* Baseline xerostomia ≥ Grade 2 by CTCAE v.5
* History of uncontrolled hypertension, myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to ICF signature and/or clinically active significant cardiac disease
* History of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months, non-invasive malignant colon polyps that have been removed).
Other protocol-defined inclusion/exclusion criteria may apply.
Study design
Enrollment target: 443 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-02-27
Estimated completion: 2033-07-19
Last updated: 2026-04-16
Interventions
Drug: Investigators choice of SoCDrug: AAA817Drug: AAA817Drug: AAA817
Primary outcomes
- • Biochemical response rate (Phase II) (from date of randomization up to approximately 24 months)
- • Adverse Events (AEs) and Serious Adverse Events (SAEs), and deaths - Phase II (from day of randomization to 30 days after End of Treatment or (last AAA817 dose date + 55 days, last dose date of SoC + 30 days), whichever is later)
- • Tolerability of the proposed dose of AAA817- Phase II (From on-treatment period which start from the first dose of study treatment until 30 days post-last dose date for SoC and 55 days post last-dose for AAA817)
Sponsor
Novartis Pharmaceuticals · industry
Contacts & investigators
ContactNovartis Pharmaceuticals · contact · novartis.email@novartis.com · 1-888-669-6682
ContactNovartis Pharmaceuticals · contact · +41613241111
All locations (61)
VA Greater LA Healthcare SystemRecruiting
Los Angeles, California, United States
Stanford University Medical CenterRecruiting
Palo Alto, California, United States
University Cancer and Blood Center LLCRecruiting
Athens, Georgia, United States
Indiana UniversityRecruiting
Indianapolis, Indiana, United States
University of Kansas HospitalRecruiting
Kansas City, Kansas, United States
Dana Farber Cancer InstituteRecruiting
Boston, Massachusetts, United States
WA Uni School Of MedRecruiting
St Louis, Missouri, United States
Nebraska Cancer SpecialistsRecruiting
Omaha, Nebraska, United States
New Jersey Urology LLCRecruiting
Voorhees Township, New Jersey, United States
Associated Med Professionals of NYRecruiting
Syracuse, New York, United States
Montefiore Medical CenterRecruiting
The Bronx, New York, United States
Carolina Urologic Research CenterRecruiting
Myrtle Beach, South Carolina, United States
Urology San AntonioRecruiting
San Antonio, Texas, United States
Medical College Of WisconsinRecruiting
Milwaukee, Wisconsin, United States
Novartis Investigative SiteRecruiting
Darlinghurst, New South Wales, Australia
Novartis Investigative SiteRecruiting
Herston, Queensland, Australia
Novartis Investigative SiteRecruiting
São Paulo, São Paulo, Brazil
Novartis Investigative SiteRecruiting
São Paulo, São Paulo, Brazil
Novartis Investigative SiteRecruiting
Fuzhou, Fujian, China
Novartis Investigative SiteRecruiting
Wuhan, Hubei, China
Novartis Investigative SiteRecruiting
Wuhan, Hubei, China
Novartis Investigative SiteRecruiting
Nanjing, Jiangsu, China
Novartis Investigative SiteRecruiting
Nanjing, Jiangsu, China
Novartis Investigative SiteRecruiting
Shenyang, Liaoning, China
Novartis Investigative SiteRecruiting
Xian, Shanxi, China
Novartis Investigative SiteRecruiting
Xian, Shanxi, China
Novartis Investigative SiteRecruiting
Chengdu, Sichuan, China
Novartis Investigative SiteRecruiting
Beijing, China
Novartis Investigative SiteRecruiting
Beijing, China
Novartis Investigative SiteRecruiting
Guangzhou, China
Novartis Investigative SiteRecruiting
Shanghai, China
Novartis Investigative SiteRecruiting
Shanghai, China
Novartis Investigative SiteRecruiting
Tianjin, China
Novartis Investigative SiteRecruiting
Hong Kong, Hong Kong
Novartis Investigative SiteRecruiting
Beersheba, Israel
Novartis Investigative SiteRecruiting
Haifa, Israel
Novartis Investigative SiteRecruiting
Petah Tikva, Israel
Novartis Investigative SiteRecruiting
Ramat Gan, Israel
Novartis Investigative SiteRecruiting
Tel Aviv, Israel
Novartis Investigative SiteRecruiting
Kashiwa, Chiba, Japan
Novartis Investigative SiteRecruiting
Sapporo, Hokkaido, Japan
Novartis Investigative SiteRecruiting
Kobe, Hyōgo, Japan
Novartis Investigative SiteRecruiting
Yokohama, Kanagawa-ku, Japan
Novartis Investigative SiteRecruiting
Chiba, Japan
Novartis Investigative SiteRecruiting
Fukuoka, Japan
Novartis Investigative SiteRecruiting
Fukuoka, Japan
Novartis Investigative SiteRecruiting
Fukushima, Japan
Novartis Investigative SiteRecruiting
Ishikawa, Japan
Novartis Investigative SiteRecruiting
Kyoto, Japan
Novartis Investigative SiteRecruiting
Singapore, Singapore
Novartis Investigative SiteRecruiting
Singapore, Singapore
Novartis Investigative SiteRecruiting
Singapore, Singapore
Novartis Investigative SiteRecruiting
Seoul, South Korea
Novartis Investigative SiteRecruiting
Seoul, South Korea
Novartis Investigative SiteRecruiting
Seoul, South Korea
Novartis Investigative SiteRecruiting
Basel, Switzerland
Novartis Investigative SiteRecruiting
Bern, Switzerland
Novartis Investigative SiteRecruiting
Taipei, Taiwan
Novartis Investigative SiteRecruiting
Taipei, Taiwan
Novartis Investigative SiteRecruiting
Taipei, Taiwan
Novartis Investigative SiteRecruiting
Taoyuan District, Taiwan